Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jin Li

Neurology Hawthorne, NY Medical Doctor

NPI 1710974357 CMS profile 259768

19 Bradhurst Ave, Ste. 2850, Hawthorne, NY 10532

Open in the dashboard

General payments

$96,972

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jin Li of Hawthorne, NY is reported in the CMS Open Payments database as having received $96,972 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,553 21
2024 General $17,289 25
2023 General $28,831 44
2022 General $15,025 56
2021 General $15,965 41
2020 General $9,418 19
2019 General $891 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jin Li
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jin Li were reported at $9,553. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jin Li Neurology median Middle half National median
2019 $891 $474 $118–$2,177 $163
2020 $9,418 $367 $82–$2,309 $114
2021 $15,965 $438 $104–$2,547 $132
2022 $15,025 $442 $103–$2,388 $149
2023 $28,831 $464 $119–$2,312 $160
2024 $17,289 $468 $119–$2,323 $164
2025 $9,553 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $41,357 90 payments
  2. Alexion Pharmaceuticals, Inc. $40,449 55 payments
  3. Allergan Inc. $12,625 21 payments
  4. Bausch Health US, LLC $500 1 payment
  5. Biogen, Inc. $338 3 payments
  6. Lilly USA, LLC $215 10 payments
  7. Neurocrine Biosciences, Inc. $163 1 payment
  8. Globus Medical, Inc. $154 1 payment
  9. UCB, Inc. $138 1 payment
  10. Gilead Sciences, Inc. $125 1 payment
  11. Other $909 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $77,878 36 payments
  2. Consulting Fee $6,670 3 payments
  3. Travel and Lodging $6,312 31 payments
  4. Food and Beverage $6,112 139 payments
  5. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $41,306 64 payments
  2. ULTOMIRIS $40,353 51 payments
  3. QULIPTA $13,196 32 payments
  4. UBRELVY Neuroscience $9,302 15 payments
  5. MIGRANAL $500 1 payment
  6. TYSABRI $300 2 payments
  7. EMGALITY $214 9 payments
  8. REYVOW $214 9 payments
  9. BOTOX $193 6 payments
  10. INGREZZA $163 1 payment
  11. Other $1,703 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,013

Median for Neurology: 833

Drug cost

$2,802,622

Median for Neurology: $202,670

Branded share of claims

36.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 62 $1,648,284
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $362,031
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 26 $313,290
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 32 $220,527
Nurtec Odt Rimegepant Sulfate Brand 63 $106,201
Ubrelvy Ubrogepant Brand 48 $60,029
Aimovig Autoinjector Erenumab-Aooe Brand 48 $54,665
Qulipta Atogepant Brand 13 $17,129
Sumatriptan Succinate Generic 51 $5,193
Pyridostigmine Bromide Generic 47 $2,915

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$171,962

Of which drugs: $112,595

Medicare patients

213

Average age 71

Services billed

23,498

129 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 67%
Diabetes 35%
Ischemic heart disease 35%
Depression 34%
Atrial fibrillation 26%
Heart failure 22%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 39 22,800 $112,582

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $11,870
$11,870 — —
UBRELVY
  • AbbVie, Inc. $5,229
$5,229 48 —
BOTOX
  • AbbVie, Inc. $169
$169 — 22,800
VYVGART Hytrulo
  • ARGENX US, INC. $18
$18 — —
QULIPTA
  • AbbVie, Inc. $4
$4 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record